menu
    • menu
    [{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"VIVEbiotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"convertible CAR-T cells","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xyphos Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"GO Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Xyphos Biosciences","amount2":0.78000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"Phanes Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Xyphos Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Xyphos Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"Kelonia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xyphos Biosciences","amount2":0.83999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.83999999999999997,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Xyphos Biosciences","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xyphos Biosciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Xyphos Biosciences \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Xyphos Biosciences \/ Xyphos Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Xyphos Biosciences

    Menu

    Xyphos Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Poseida Therapeutics, Inc

                            Deal Size : $600.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas and Poseida Enter Research Collaboration for Cell Therapies

                            Details : Poseida and Xyphos will combine their technologies to develop a CAR-T construct targeting solid tumors, creating two convertibleCAR® product candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $50.0 million

                            May 01, 2024

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Poseida Therapeutics, Inc

                            Deal Size : $600.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Kelonia Therapeutics

                            Deal Size : $840.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astellas and Kelonia Sign Agreement to Develop Novel Immuno-Oncology Therapeutics

                            Details : Under the term of the license agreement, the companies plan to combine Kelonia's iGPS with Xyphos' ACCEL technology to develop innovative in vivo CAR-T Cell therapies for Immuno-oncology.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $40.0 million

                            February 15, 2024

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Kelonia Therapeutics

                            Deal Size : $840.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Talem Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement w...

                            Details : The companies will jointly conduct research activities to identify and optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies, targeting an undisclosed target in the TME, as potential therapeutic development candidate...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Talem Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Phanes Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Phanes Therapeutics Entered Into A Research Collaboration With Xyphos Biosciences, Inc., An Astellas Company

                            Details : The collaboration will leverage Phanes’ proprietary technology platforms, PACbody and SPECpair, in the evaluation of cell therapies in oncology. The company has its proprietary technology platforms to develop novel biologics that address high unmet med...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 06, 2023

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Phanes Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : GO Therapeutics

                            Deal Size : $783.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies f...

                            Details : GO will lead the collaboration to discover high-affinity antibodies against the two targets, and Astellas will be responsible for research activities, clinical development and commercialization of the therapeutics derived from the antibodies for Immuno-O...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $20.5 million

                            June 01, 2022

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : GO Therapeutics

                            Deal Size : $783.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Xyphos Biosciences

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lentiviral vectors,convertible CAR-T cells

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : VIVEbiotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            VIVEbiotech Collaborates with Xyphos Biosciences for Clinical Development Support Of Convertible CAR-T™ Cell...

                            Details : The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 04, 2020

                            Lead Product(s) : Lentiviral vectors,convertible CAR-T cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : VIVEbiotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth